Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose
- PMID: 34804634
- PMCID: PMC8601657
- DOI: 10.4236/jct.2021.129044
Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose
Abstract
Purpose: Recent studies of radiotherapy (RT) for stage III non-small-cell lung cancer (NSCLC) have associated high dose to the heart with cardiac toxicity and decreased overall survival (OS). We used advanced statistical techniques to account for correlations between dosimetric variables and more accurately determine the range of heart doses which are associated with reduced OS in patients receiving RT for stage III NSCLC.
Methods: From 2006 to 2013, 119 patients with stage III NSCLC received definitive RT at our institution. OS data was obtained from institutional tumor registry. We used multivariate Cox model to determine patient specific covariates predictive for reduced overall survival. We examined age, prescription dose, mean lung dose, lung V20, RT technique, stage, chemotherapy, tumor laterality, tumor volume, and tumor site as candidate covariates. We subsequently used novel statistical techniques within multivariate Cox model to systematically search the whole heart dose-volume histogram (DVH) for dose parameters associated with OS.
Results: Patients were followed until death or 2.5 to 81.2 months (median 30.4 months) in those alive at last follow up. On multivariate analysis of whole heart DVH, the dose of 51 Gy was identified as a threshold dose above which the dose volume relationship becomes predictive for OS. We identified V55Gy (percentage of the whole heart volume receiving at least 55 Gy) as the best single DVH index which can be used to set treatment optimization constraints (Hazard Ratio = 1.044 per 1% increase in heart volume exposed to at least 55 Gy, P = 0.03). Additional characteristics correlated with OS on multivariate analysis were age, stage (IIIA/IIIB), and administration of chemotherapy.
Conclusion: Doses above 51 Gy, applied to small volumes of the heart, are associated with worse OS in stage III NSCLC patients treated with definitive RT. Higher stage, older age and lack of chemotherapy were also associated with reduced OS.
Keywords: Cardiac Toxicity; Lung Cancer; Lung Radiation Therapy; Non-Small Cell Lung Cancer; Radiation Toxicity.
Conflict of interest statement
Conflicts of Interest Dr. Schild reports writing and editing for UpToDate. No conflicts exist for remaining authors.
Similar articles
-
Impact of Cardiac Dose on Overall Survival in Lung Stereotactic Body Radiotherapy (SBRT) Compared to Conventionally Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC).J Cancer Ther. 2021 Jul;12(7):409-423. doi: 10.4236/jct.2021.127036. J Cancer Ther. 2021. PMID: 34367717 Free PMC article.
-
Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.Clin Lung Cancer. 2017 May;18(3):293-298. doi: 10.1016/j.cllc.2016.12.007. Epub 2016 Dec 22. Clin Lung Cancer. 2017. PMID: 28089158 Free PMC article.
-
Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):346-355. doi: 10.1016/j.ijrobp.2019.05.064. Epub 2019 Jun 5. Int J Radiat Oncol Biol Phys. 2019. PMID: 31175902
-
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2. Hematol Oncol Clin North Am. 2004. PMID: 15005280 Review.
-
Cardiac toxicity of lung cancer radiotherapy.Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):13-19. doi: 10.1016/j.rpor.2019.10.007. Epub 2019 Nov 14. Rep Pract Oncol Radiother. 2020. PMID: 31762693 Free PMC article. Review.
Cited by
-
Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy.Cancers (Basel). 2023 Feb 17;15(4):1277. doi: 10.3390/cancers15041277. Cancers (Basel). 2023. PMID: 36831618 Free PMC article.
-
Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.JACC CardioOncol. 2023 Oct 4;5(6):775-787. doi: 10.1016/j.jaccao.2023.08.007. eCollection 2023 Dec. JACC CardioOncol. 2023. PMID: 38205000 Free PMC article.
-
Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.Br J Cancer. 2025 Mar;132(4):401-407. doi: 10.1038/s41416-024-02926-x. Br J Cancer. 2025. PMID: 39775164 Free PMC article. No abstract available.
-
Cardiotoxicity following thoracic radiotherapy for lung cancer.Br J Cancer. 2025 Mar;132(4):311-325. doi: 10.1038/s41416-024-02888-0. Epub 2024 Nov 6. Br J Cancer. 2025. PMID: 39506136 Free PMC article. Review.
-
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial.Diagnostics (Basel). 2023 May 12;13(10):1717. doi: 10.3390/diagnostics13101717. Diagnostics (Basel). 2023. PMID: 37238201 Free PMC article.
References
-
- Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. (2013) Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal: Cardiovascular Imaging, 14, 721–740. 10.1093/ehjci/jet123 - DOI - PubMed
-
- Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. (2017) Cardiac Toxicity after Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. Journal of Clinical Oncology, 35, 1387–1394. 10.1200/JCO.2016.70.0229 - DOI - PMC - PubMed
-
- Xue J, Han C, Jackson A, Hu C, Yao H, Wang W, et al. (2019) Doses of Radiation to the Pericardium, Instead of Heart, are Significant for Survival in Patients with Non-Small Cell Lung Cancer. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 133, 213–219. 10.1016/J.radonc.2018.10.029 - DOI - PMC - PubMed
-
- Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, et al. (2017) Heart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Dose-Escalation Trials for Stage III Non-Small-Cell Lung Cancer. Radiotherapy and Oncology, 125, 293–300. 10.1016/j.radonc.2017.10.001 - DOI - PMC - PubMed
Grants and funding
- U10 CA035267/CA/NCI NIH HHS/United States
- N01 CA035431/CA/NCI NIH HHS/United States
- U10 CA037404/CA/NCI NIH HHS/United States
- N01 CA035119/CA/NCI NIH HHS/United States
- U10 CA035101/CA/NCI NIH HHS/United States
- U10 CA035113/CA/NCI NIH HHS/United States
- U10 CA035431/CA/NCI NIH HHS/United States
- U10 CA035119/CA/NCI NIH HHS/United States
- U10 CA025224/CA/NCI NIH HHS/United States
- U10 CA035090/CA/NCI NIH HHS/United States
- U10 CA035103/CA/NCI NIH HHS/United States
- U10 CA063848/CA/NCI NIH HHS/United States
- U10 CA035195/CA/NCI NIH HHS/United States
- U10 CA035415/CA/NCI NIH HHS/United States
- U10 CA063849/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources